Update in HIV-Related Therapies and Important Medication Considerations
This activity will provide pharmacists, residents, interns and technicians knowledge of HIV practice guidelines including pre-exposure prophylaxis of HIV (PrEP), treatment of HIV-infected, and post-exposure prophylaxis (PEP) with an emphasis on two newly approved FDA HIV therapies. These new therapies, Apretude and Cabenuva will be reviewed in-depth allowing pharmacy personnel to learn about important drug considerations including their place in therapy, efficacy, administration technique, dosing regimen, side effects profile, drug-drug interactions and more. This presentation will further advance the understanding and clinical capabilities of pharmacy personnel in HIV management, in order to provide patients with the best health care possible.
Target Audience
The activity is intended for pharmacists and pharmacy technicians.
Learning Objectives
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Apply current HIV guideline recommendations for the pre-exposure prophylaxis and treatment of HIV in a case-based scenario.
- Evaluate the literature on the recently approved therapies for the pre-exposure prophylaxis and treatment of HIV.
- Assess for any drug-drug interactions and any other important medication considerations related to Apretude and Cabenuva.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Recognize brand and generic names of new HIV treatment and prevention options.
Additional Information
Attachment | Size |
---|---|
![]() | 134.81 KB |
Faculty/Presenter
Douglas Hutchison, PharmD
PGY1 Community Pharmacy Resident
Ochsner Medical Center
Planning Committee
Amanda Mooney, PharmD
Pharmacist
Ochsner Medical Center
Claire Ozoral, PharmD, BCPS
Pharmacist
Ochsner Medical Center
Natalie Tucker, PharmD, BCCCP
Pharmacist
Ochsner Medical Center
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Providership Statment
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement:
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.
UAN JA0006103-9999-22-115-L02-P
UAN JA0006103-9999-22-115-L02-T
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician